Skip to main content

Piper Sandler Sticks to Their Buy Rating for ICU Medical (ICUI)

Tipranks - Tipranks - Thu Feb 19, 6:29AM CST

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on ICU Medical, with a price target of $172.00.

President's Day Sale - 70% Off

Bednar covers the Healthcare sector, focusing on stocks such as Masimo, NovoCure, and Align Tech. According to TipRanks, Bednar has an average return of -4.5% and a 40.22% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ICU Medical with a $173.50 average price target.

See the top stocks recommended by analysts >>

Based on ICU Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $536.99 million and a GAAP net loss of $3.4 million. In comparison, last year the company earned a revenue of $589.13 million and had a GAAP net loss of $32.98 million

Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICUI in relation to earlier this year.

Read More on ICUI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).